Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Wassenaar

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
WMJ : Official Publication of the State Medical Society of Wisconsin|October 13, 2005
Do prophylactic anticonvulsants in patients with brain tumors decrease the incidence of seizures?Tim Wassenaar, David Feldstein
Clinical Lymphoma, Myeloma & Leukemia|October 30, 2024
Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network StudyJulie E Chang, Danielle McQuinn, Meredith Hyun, et al.
Cancer|June 17, 2015
A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network studyTimothy S Fenske, Namrata M Shah, Kyung Mann Kim, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
WMJ : Official Publication of the State Medical Society of Wisconsin|October 13, 2005
Do prophylactic anticonvulsants in patients with brain tumors decrease the incidence of seizures?Tim Wassenaar, David Feldstein
Clinical Lymphoma, Myeloma & Leukemia|October 30, 2024
Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network StudyJulie E Chang, Danielle McQuinn, Meredith Hyun, et al.
Cancer|June 17, 2015
A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network studyTimothy S Fenske, Namrata M Shah, Kyung Mann Kim, et al.
Pageof 1